Phase 4 N=42 Randomized Double-blind Treatment

Safety of Remifentanil Infusion

Urinary Tract Problem

Bottom Line

View on ClinicalTrials.gov: NCT01303627 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Jun 2012

Primary outcome: Primary: Smooth cLMA Removal Condition (Score 1) — 86; 40 percentage of participants — p=<0.05

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: remifentanil (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Diskapi Teaching and Research Hospital
Primary completion: Mar 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Smooth cLMA Removal Condition (Score 1)	86; 40	<0.05 sig

Summary

The effect of maintenance remifentanil infusion with target controlled infusion during laryngeal mask airway removal on hemodynamic parameters and emergence quality is going to be investigated.

Eligibility Criteria

Inclusion Criteria

ASA I-II status
aged 18-60 years old
presenting for ureterorenoscopy

Exclusion Criteria

history of hypertension
asthma and chronic obstructive lung disease
recent respiratory tract infections

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01303627). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.